How to Build a CMC Strategy That Enables Fast IND Without Rework Later
A Practical Framework for Early-Phase Programs Selecting the Right CDMO Partner
For the entire biopharma industry, early development is a defining moment. The decisions made in the first months of a program—about the molecule, the cell line, the analytical package, and the manufacturing strategy—set the trajectory for everything that follows. Yet these decisions are often made under intense pressure with timelines looming and a lack of information. Investors expect rapid progress toward first-in-human studies. Budgets are constrained. And early-stage teams, many of whom come from academic or discovery settings, must suddenly navigate the structure, rigor, and complexity of a GMP-aligned development pathway.
This combination of urgency, limited resources, and unfamiliar requirements creates fertile ground for avoidable missteps. Program teams aim to conserve capital, move quickly, and demonstrate meaningful milestones. But speed achieved the wrong way introduces fragility, not momentum. A rushed choice of molecule or cell line, a process not sufficiently developed to withstand GMP execution, or an underbuilt analytical package can lead to batch failures, regulatory delays, and expensive rework that erodes both timelines and credibility.